multiple-sclerosis

Documents about multiple-sclerosis

• Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients#842856ClinicalTrials.gov
• Prospective Stratification of Infectious Risks in Multiple Sclerosis#904340ClinicalTrials.gov
• Estudio de proteínas plasmáticas y en líquido cefalorraquídeo como biomarcadores de progresión a fase secundaria en la esclerosis múltiple#325721Gestión del Repositorio Documental de la Universidad de Salamanca
• Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis#254358IRIS
• Non-infectious environmental risk factors of multiple sclerosis: Mechanisms and intervention windows for prevention#139729HAL (France)
• The genetic architecture of multiple sclerosis in 2026: From susceptibility to disease progression#218053HAL (France)
• Reproductive Health, Sexuality, and Pregnancy Decision-Making in Women with Multiple Sclerosis: A Qualitative Study#315276Muğla Sıtkı Koçman University Institutional Repository
• Colorectal cancer screening in individuals with multiple sclerosis: A mixed-methods study#471919HAL (France)
• A multi-outcome prognostic score for therapeutic responses in multiple sclerosis#624960HAL (France)
• A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies#642412Europe PMC
• Study of Diroximel Fumarate in the Real-World Setting#804914ClinicalTrials.gov
• Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis#806750ClinicalTrials.gov
• Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex#811246ClinicalTrials.gov
• Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery#837380ClinicalTrials.gov
• 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis#850391ClinicalTrials.gov
• A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple Sclerosis#850999ClinicalTrials.gov
• Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis#887023ClinicalTrials.gov
• A Digital Therapeutic to Improve Insomnia in Multiple Sclerosis: A Randomized Controlled Trial.#891303ClinicalTrials.gov
• Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists#893078ClinicalTrials.gov
• A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology#907679ClinicalTrials.gov
• Colecalciferol as an Add-on Treatment to Interferon-beta-1b for Treatment of Multiple Sclerosis (MS)#913044ClinicalTrials.gov
• Effect of Aerobic Training vs Balance Training on Fatigue Symptom in Multiple Sclerosis Patient (FATI-gate)#916690ClinicalTrials.gov
• Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)#918615ClinicalTrials.gov
• A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)#966242ClinicalTrials.gov
• Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases#217044ClinicalTrials.gov
• Natalizumab for multiple sclerosis.#433709NCBI PubMed Central
• Multiple sclerosis: 2026 update.#433844NCBI PubMed Central
• Scan-Rescan Sub-Study of MS PATHS#830322ClinicalTrials.gov
• Exploring attitudes and acceptance of artificial intelligence in multiple sclerosis from the patient perspective#331247PLOS
• A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis#405123ClinicalTrials.gov
• Brain age gap in multiple sclerosis: associated with disability but independent of serum biomarkers#610829Bielefeld Pub
• Genetic modification of obesity-associated disability progression in multiple sclerosis#784507Europe PMC
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)#802243ClinicalTrials.gov
• Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.#811196ClinicalTrials.gov
• A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis#813759ClinicalTrials.gov
• A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple Sclerosis#848758ClinicalTrials.gov
• Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity#854720ClinicalTrials.gov
• Medical Education for Better Multiple Sclerosis Outcomes#859445ClinicalTrials.gov
• Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy#874906ClinicalTrials.gov
• Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Sclerosis#877034ClinicalTrials.gov
• Impact of Exercise Training on Serum Neurofilament Light Chain (NfL), Brain Volumetry, and Functional Outcomes in Multiple Sclerosis#891635ClinicalTrials.gov
• The Effect of Cigarette Smoke on Sleep Quality and Physical Activity in People With Multiple Sclerosis#894837ClinicalTrials.gov
• Transcutaneous Tibial Neuro-stimulation to Improve Voiding Dysfunction in Multiple Sclerosis.#895685ClinicalTrials.gov
• Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With Multiple Sclerosis#915118ClinicalTrials.gov
• Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)#916500ClinicalTrials.gov
• Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis#967600ClinicalTrials.gov
• Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)#968452ClinicalTrials.gov
• Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial#825544ClinicalTrials.gov
• Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease#853118ClinicalTrials.gov
• The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Walking, Balance, and Cognitive Functions in Individuals With Multiple Sclerosis#869678ClinicalTrials.gov